PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 29, 2018Cardiovascular Diabetology71 citationsOpen Access

Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up

CSCelestino SarduMBMichelangela BarbieriMBMaria Luisa Balestrieri

Structured PICO

Does thrombus aspiration before PPCI reduce mortality and re-hospitalization in STEMI patients, particularly those with hyperglycemia?

P
Population
3,166 patients with first STEMI (2,504 completed the study), including a subgroup of 897 patients with hyperglycemia during the event (glycaemia > 140 mg/dl).
I
Intervention
Thrombus aspiration before primary percutaneous coronary intervention (PPCI)
C
Comparator
Primary percutaneous coronary intervention (PPCI) alone
O
Outcome
All-cause mortality, cardiac mortality and re-hospitalization for coronary disease, heart failure and stroke at 1 yearcomposite

Thrombus aspiration during primary PCI may offer a mortality benefit specifically in STEMI patients presenting with hyperglycemia, despite lacking benefit in the overall STEMI population.

Abstract

OBJECTIVES: We evaluate whether the thrombus aspiration (TA) before primary percutaneous coronary intervention (PPCI) may improve STEMI outcomes in hyperglycemic patients. BACKGROUND: The management of hyperglycemic patients during STEMI is unclear. METHODS: We undertook an observational cohort study of 3166 first STEMI. Patients were grouped on the basis of whether they received TA or not. Moreover, among these patients we selected a subgroup of STEMI patients with hyperglycemia during the event (glycaemia > 140 mg/dl). The endpoint at 1 year included all-cause mortality, cardiac mortality and re-hospitalization for coronary disease, heart failure and stroke. RESULTS: One-thousand STEMI patients undergoing PPCI to plus TA (TA-group) and 1504 STEMI patients treated with PPCI alone (no-TA group) completed the study. In overall study-population, Kaplan-Meier-analysis demonstrated no significant difference in mortality rates between patients with and without TA (P = 0.065). After multivariate Cox-analysis (HR: 0.94, 95% CI 0.641-1.383) and the addition of propensity matching (HR: 0.86 95% CI 0.412-1.798) TA was still not associated with decreased mortality. By contrast, in hyperglycemic subgroup STEMI patients (TA-group, n = 331; no-TA group, n = 566), Kaplan-Meier-analysis demonstrated a significantly lower mortality (P = 0.019) in TA-group than the no-TA group. After multivariate Cox-analysis (HR: 0.64, 95% CI 0.379-0.963) and the addition of propensity matching (HR: 0.54, 95% CI 0.294-0.984) TA was still associated with decreased mortality. CONCLUSIONS: TA was not associated with lower mortality in PPCI for STEMI when used in our large all-comer cohort. Conversely, TA during PPCI for STEMI reduces clinical outcomes in hyperglycemic patients. Trial registration NCT02817542. 25th, June 2016.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sardu et al. (2018) studied this question.

synapsesocial.com/papers/6a76a258656dd99464ec2474https://doi.org/10.1186/s12933-018-0795-8
Ask AI
Helpful
Bookmark
Share
View Full Paper